- Ariad Pharmaceuticals (ARIA) collapses 59% after the company says that it's suspending the enrollment of new patients in trials for its Iclusig treatment for chronic myeloid leukemia.
- The pause follows an increase in the rate of cardiac problems in patients who received Iclusig.
- Pending FDA approval, Ariad hopes to resume enrollment with lower doses of the drug. Patients already on the medicine will continue to do so but with smaller doses.
- The U.S. prescribing information for Iclusig remains unchanged. (PR)
Ariad shares plunge after it pauses enrollment for leukemia drug trial
From other sites
at CNBC.com (Jan 16, 2015)
at CNBC.com (Jan 14, 2015)
Video at CNBC.com (Jan 13, 2015)
at CNBC.com (Jan 13, 2015)
at CNBC.com (Jan 9, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs